Wall Street brokerages expect ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) to post earnings per share of ($0.12) for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for ZIOPHARM Oncology’s earnings. The highest EPS estimate is ($0.09) and the lowest is ($0.14). ZIOPHARM Oncology reported earnings of ($0.09) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 33.3%. The firm is scheduled to announce its next quarterly earnings report on Tuesday, May 9th.
According to Zacks, analysts expect that ZIOPHARM Oncology will report full year earnings of ($0.56) per share for the current year, with EPS estimates ranging from ($0.78) to ($0.43). For the next year, analysts expect that the company will post earnings of ($0.67) per share, with EPS estimates ranging from ($0.96) to ($0.45). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that follow ZIOPHARM Oncology.
A number of equities analysts have recently weighed in on the stock. Griffin Securities reaffirmed a “buy” rating and issued a $23.00 price target (up from $21.00) on shares of ZIOPHARM Oncology in a research note on Friday, February 10th. Zacks Investment Research downgraded shares of ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a research report on Thursday, April 6th. Finally, JPMorgan Chase & Co. reissued a “hold” rating on shares of ZIOPHARM Oncology in a research report on Thursday, January 12th. One research analyst has rated the stock with a sell rating, four have given a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $10.15.
A number of institutional investors have recently bought and sold shares of the company. Creative Planning increased its position in ZIOPHARM Oncology by 289.3% in the first quarter. Creative Planning now owns 57,863 shares of the biotechnology company’s stock valued at $367,000 after buying an additional 43,000 shares during the last quarter. Highbridge Capital Management LLC acquired a new position in ZIOPHARM Oncology during the fourth quarter valued at approximately $164,000. Teachers Advisors LLC increased its position in ZIOPHARM Oncology by 1.9% in the fourth quarter. Teachers Advisors LLC now owns 198,508 shares of the biotechnology company’s stock valued at $1,062,000 after buying an additional 3,699 shares during the last quarter. Vident Investment Advisory LLC increased its position in ZIOPHARM Oncology by 5.8% in the fourth quarter. Vident Investment Advisory LLC now owns 114,980 shares of the biotechnology company’s stock valued at $615,000 after buying an additional 6,260 shares during the last quarter. Finally, Norges Bank acquired a new position in ZIOPHARM Oncology during the fourth quarter valued at approximately $5,556,000. 41.26% of the stock is currently owned by hedge funds and other institutional investors.
Shares of ZIOPHARM Oncology (NASDAQ:ZIOP) traded up 0.28% during midday trading on Monday, hitting $7.10. The stock had a trading volume of 1,216,951 shares. ZIOPHARM Oncology has a 12-month low of $4.45 and a 12-month high of $8.86. The firm’s market cap is $927.94 million. The company’s 50-day moving average price is $6.47 and its 200-day moving average price is $6.16.
ZIOPHARM Oncology Company Profile
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ZIOPHARM Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.